Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Neoplasms 1Muscle Neoplasms 1HIV Infections 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

Doxorubicin 62Ifosfamide 39Gemcitabine 29Radiotherapy 27Filgrastim 27Cyclophosphamide 26Docetaxel 19Vincristine 18pembrolizumab 17Etoposide 17pazopanib 16Cisplatin 16Nivolumab 15Trabectedin 14apatinib 13Magnetic Resonance Spectroscopy 13Carboplatin 12Irinotecan 11Bevacizumab 11anlotinib 10Temozolomide 10Surgical Procedures, Operative 10Sirolimus 10camrelizumab 9Sorafenib 9Paclitaxel 9Ipilimumab 9Injections 9Dactinomycin 9Topotecan 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma × Tumor Necrosis Factor-alpha × Clear all
NCT00019968 2023-10-31

Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
Sarcoma

Neoplasms, Sarcoma, Muscle Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡